About this Research Topic
Colorectal cancer is the third most common cancer and the third most common cause of cancer-related death in both men and women in the United States. In the past decades, new therapeutic modalities such as targeted therapy, immunotherapy and combination therapies have been developed. However, pressing issues including safety, cytotoxicity and resistance remain the biggest obstacles in improving treatment efficacy. Nanomaterials are nano-sized (1-100nm) materials that have huge potential to be developed into anticancer therapeutics. Examples of anticancer nanomaterials include nanoparticles, liposomes, extracellular vesicles, nanoemulsions, dendrimers, graphene, etc. Depending on the types of nanomaterials, each possesses unique characteristics and may carry temperature- and pH-stimuli-responsive properties which can enhance cancer treatment. More importantly, nanomaterial can be easily engineered or modified to suit the anticancer application. One of the classical examples is the development of drug nanocarrier, in which the anticancer drug is loaded or conjugated with the nanomaterial, not only to serve as a ‘double-edge sword’ therapeutics to eradicate the tumor, but to overcome current limitations such as increasing biocompatibility, tumor penetration, and target selectivity. Moreover, nanomaterials can be utilized in combination with anticancer drugs to reduce off-target cytotoxicity and overcome drug resistance.
We welcome any Reviews or Original Research articles that will contribute significantly to this Research Topic. Such work may include (but is not limited to) the introduction of novel nanomaterial-based anticancer therapeutics and the development of new-era nanotherapeutics that could address pressing issues such as drug biocompatibility, cytotoxicity, tumor targeting, etc in treating colorectal cancer, both using preclinical or animal models. High-quality research works related to the combination use of nanomaterials with current anticancer drugs, potential therapeutics under investigation, and/or radiation-based therapies which enhance the therapeutic efficacy in colorectal cancer will also be considered for publication.
Specifically, research focusing on the following subtopics will be highly welcome.
● Tumor-targeting nanomaterial for colorectal cancer experimental therapies in animal models or other preclinical models
● Generation/synthesis of safe and biocompatible therapeutic nanomaterial
● Smart nanomaterials development to overcome anticancer drug resistance
● pH- and temperature-stimuli-responsive nanotherapeutics to enhance colorectal cancer treatment
● The use of nanomaterial to enhance current anticancer therapies such as targeted therapy, radiotherapy or immunotherapy
● The use of nanomaterial to eradicate tumorigenic microbes in colorectal cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
We welcome any Reviews or Original Research articles that will contribute significantly to this Research Topic. Such work may include (but is not limited to) the introduction of novel nanomaterial-based anticancer therapeutics and the development of new-era nanotherapeutics that could address pressing issues such as drug biocompatibility, cytotoxicity, tumor targeting, etc in treating colorectal cancer, both using preclinical or animal models. High-quality research works related to the combination use of nanomaterials with current anticancer drugs, potential therapeutics under investigation, and/or radiation-based therapies which enhance the therapeutic efficacy in colorectal cancer will also be considered for publication.
Specifically, research focusing on the following subtopics will be highly welcome.
● Tumor-targeting nanomaterial for colorectal cancer experimental therapies in animal models or other preclinical models
● Generation/synthesis of safe and biocompatible therapeutic nanomaterial
● Smart nanomaterials development to overcome anticancer drug resistance
● pH- and temperature-stimuli-responsive nanotherapeutics to enhance colorectal cancer treatment
● The use of nanomaterial to enhance current anticancer therapies such as targeted therapy, radiotherapy or immunotherapy
● The use of nanomaterial to eradicate tumorigenic microbes in colorectal cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: nanomaterial, nanocarrier, colorectal cancer, therapeutics, limitation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
